Modality
Nanobody
MOA
CGRPant
Target
Menin
Pathway
NF-κB
DLBCLADHD
Development Pipeline
Preclinical
Sep 2024
PreclinicalCurrent
NCT06901930
2,718 pts·ADHD
2024-09→TBD·Completed
2,718 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-12-048mo awayFast Track· DLBCL
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Complet…
Catalysts
Fast Track
2026-12-04 · 8mo away
DLBCL
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06901930 | Preclinical | ADHD | Completed | 2718 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| INC-2432 | Incyte | Phase 2 | CD47 |